Drugs / 89Zr-trastuzumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02065609 | Feb 2014 → Dec 2017 | breast cancer | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04757090 | Dec 2021 → Dec 2023 | — | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT01832051 | Mar 2013 → Jun 2015 | breast cancer | University Medical Center Groningen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-Trastuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02065609 ↗ |
| Modality | Diagnostic / imaging agent | “89Zr-trastuzumab PET/CT imaging” NCT04757090 ↗ |